Renal disease, age, and oxazepam kinetics

Area of Science:

• Pharmacology
• Nephrology
• Geriatrics

Background:

• Oxazepam is a benzodiazepine used for anxiety.
• Its pharmacokinetics may be affected by renal function and age.
• Understanding these effects is crucial for safe and effective dosing.

Purpose of the Study:

• To investigate the impact of renal insufficiency and age on oxazepam's pharmacokinetic profile.
• To determine if dosage adjustments are needed in patients with impaired kidney function or on hemodialysis.

Main Methods:

• A pharmacokinetic study involving 13 healthy subjects, 4 patients with renal insufficiency, and 8 patients on hemodialysis.
• Measured parameters included elimination half-life (t1/2), area under the curve (AUC), unbound fraction (fup), maximum unbound concentration (Cmax,u), and intrinsic clearance (Clint).

Main Results:

• Age did not significantly influence oxazepam kinetics.
• In renal insufficiency, t1/2 prolonged to 25 hr, fup increased to 7%, but Cmax,u and Clint remained unchanged.
• In hemodialysis patients, t1/2 prolonged to 33 hr, fup increased to 6.2%, with unchanged Cmax,u and Clint. Oxazepam was found to be undialyzable.

Conclusions:

• Renal insufficiency prolongs oxazepam's elimination half-life due to increased volume of distribution of unbound drug.
• Despite prolonged half-life, intrinsic clearance and maximum unbound concentration are not altered.
• No dosage adjustment of oxazepam is necessary for patients with renal insufficiency or undergoing hemodialysis.